GSK Hopes To Triple Turnover

The Indian unit of UK-based drugmaker GlaxoSmithKline (GSK) is looking to break US$1bn in sales by 2015. GSK India hopes that a multi-pronged strategy, which includes scaling up its vaccine production business, investing heavily in its pipeline, and possibly making a midlevel acquisition, will give it the impetus to realise its ambitions.

To read the full article, please sign in or take a free trial.